Statement by the Board of Directors of Abliva regarding the public cash offer from Pharming
The Board of Directors unanimously recommends the shareholders to accept the offer.
Press releases
Abliva AB Interim Report January – September 2024
- Positive Interim Analysis of the FALCON Study Paves the Way for KL1333 Development -
Amended number of shares and votes in Abliva AB (publ)
Abliva AB (Nasdaq Stockholm: ABLI) today announces that the number of shares and votes in the Company has increased by 262,500,000, as a result of the conversion of a convertible loan announced by the ...
Abliva AB Interim Report January – June 2024
FALCON Positioned for Success Following Analysis by Independent Committee ⎮ Strong Safety Profile Confirmed, and Both Primary Endpoints Passed Futility
Positive interim analysis in Abliva’s FALCON study triggers convertible loan conversion
Abliva AB (Nasdaq Stockholm: ABLI) a clinical-stage company developing medicines for the treatment of rare and severe primary mitochondrial disease, today announced that the convertible loan of SEK 42 ...
Abliva Announces Positive Interim Analysis of the FALCON Study for KL1333 in Primary Mitochondrial Disease
-Independent committee confirms FALCON study is powered for potential success with both alternative endpoints passing futility- -Committee confirms strong safety profile of KL1333- -Abliva to hos ...
Amended number of shares and votes in Abliva AB (publ)
Abliva AB (Nasdaq Stockholm: ABLI) today announces that the number of shares and votes in the Company has increased by 103,149,954, as a result of a preferential rights issue announced by the Board of ...
Resolutions from Annual General Meeting in Abliva AB (publ) on May 23, 2024
Abliva AB (Nasdaq Stockholm: ABLI) (”Abliva” or the ”Company”) today on May 23, 2024, held its Annual General Meeting (“AGM”). A summary of the resolution follows.
Abliva AB Interim Report January – March 2024
SEK 46 million raised through preferential rights issue | Preparations for the interim analysis ongoing
Amended number of shares and votes in Abliva AB (publ)
Abliva AB (Nasdaq Stockholm: ABLI) today announces that the number of shares and votes in the Company has increased by 189,935,417, as a result of a preferential rights issue announced by the Board of ...
Abliva resolves on a directed issue of shares to guarantors in connection with the completed rights issue
Abliva AB (Nasdaq Stockholm: ABLI) ("Abliva" or the "Company") has today, based on the authorization from the extraordinary general meeting on 26 March 2024, resolved on a directed issue of 5,003,783 ...
Abliva AB Publishes 2023 Annual Report
Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage company developing drugs for the treatment of rare and severe primary mitochondrial disease, today announced that the English version of the Annual ...